HEALTH OF WOMAN. 2019.6(142): 74–79; doi 10.15574/HW.2019.142.74

V. Pyrohova, I. Kozlovskyy
Lviv national medical University named Danylo Galitsky

The objective: to study the effectiveness of complex treatment of patients with bacterial vaginosis compared with conventional antibiotic therapy.
Materials and methods. Under the supervision were 56 women of reproductive age with a diagnosis of bacterial vaginosis. Patients were divided into 4 groups. The first group included 10 women who previously received antibiotic therapy on extragenital diseases. Women are administered clindamycin vaginal cream of miconazole and followed by intravaginal drug use Feminum intima and probiotic system Laktostar Plus.
The second group consisted of 10 women who have previously received antibiotic therapy on extragenital diseases. Patients administered the drug Feminum intima and Laktostar Plus without using antibiotics.
The third group is formed of 23 women who did not receive pre-antibiotic therapy. Prescribed combination therapy that, in addition to antibacterial cream included intravaginal drug Feminum intima and probiotic system Laktostar Plus.
23 women fourth group administered antibacterial cream and then using the drug Feminum intima. Monitoring the effectiveness of the treatment was carried out by clinical and laboratory course of the disease based on the dynamic changes of complaints of patients, assessment data pH measuring (7, 21 and 60 day observation of treatment), assessment of the ecological community conducted a test system Femoflor 16 at 7 and 21 days of early treatment.
Results. In general, clinical and microbiological efficacy after completion of BV treatment in the 1^-st and 3rd groups was noted in all patients, in the 2^-nd group – in 90%, in the 4^-th group – in 83% of women. Clinical efficacy (complaint regression and objective data normalization) averaged 4.4 days in group 1, 5.8 days in group 2, 4.2 days in groups 3 and 4, 4 days – in the 4^-th group. An examination after 60 days showed that clinically relapsed BV occurred in 4 (7%) patients, 2 of whom were in the 4th observation group.
Conclusion. The results showed that the combined treatment of bacterial vaginosis with the use of antibacterial vaginal gel Feminum intima and probiotic Laktostar Plus effectively and quickly restores the vaginal environment helps eliminate dysbiosis system and the rapid return of the normal microflora vaginally, reduces the number of recurrences of bacterial vaginosis.
Key words: bacterial vaginosis, treatment, intravaginal forms, probiotics.

REFERENCES

1. Yankovskiy DS, Shirobokov VP, Antipkin YuG, Tatarchuk TF, Dyiment GS. 2015. Mikrobiom i zdorove zhenschinyi (obzor literaturyi). Reproduktivnaya endokrinologiya 24:13–28.

2. Kira EF. 2012. Bakterialnyiy vaginoz. M, MIA: 472.

3. Yankovskiy DS, Shirobokov VP, Volosovets AP, Moiseenko RA, Dyiment GS. 2014. Mikrobiom cheloveka i sovremennyie metodyi ego ozdorovleniya. Zhurn. NAMNU.

4. Kira EF, Berlev IV, Molchanov OL. 1999. Osobennosti techeniya beremennosti, rodov i poslerodovogo perioda u zhenschin s disbioticheskimi narusheniyami vlagalischa. Zhurnal akusherstva i zhenskih bolezney 2;XLVII: 8–11.

5. Shirobokov VP, Yankovskiy DS, Dyiment GS. 2010. Novyie strategii v oblasti sozdaniya i klinicheskogo ispolzovaniya probiotikov. VIsnik farmakologii ta farmatsii 2:18–30.

6. Yankovskiy DS, Dyiment GS. 2007. Uluchshenie reproduktivnogo zdorovya zhenschinyi putem optimizatsii mikroekologii pischevaritelnogo i urogenitalnogo trakta. Reproduktivnoe zdorove zhenschiny 3:148–154.

7. Swidsinski A, Mendling W, Loening-Baucke V, Ladnoff A et al. 2005. Adherent biofilms in bacterial vaginosis. Obstet Gynecol. 106: 1013–1023. https://doi.org/10.1097/01.AOG.0000183594.45524.d2; PMid:16260520

8. Patterson JL, Girerd PH, Karjane NW, Jefferson KK. 2007. Effect of biofilm phenotype on resistance of Gardnerella vaginalis to hydrogen peroxide and lactic acid. Am J Obstet Gynecol. 197: 170. https://doi.org/10.1016/j.ajog.2007.02.027; PMid:17689638 PMCid:PMC2020809

9. McMillan A, Dell M, Zellar MP, Cribby S, Martz S, Hong E et al. 2011. Disruption of urogenital biofilms by lactobacilli. Colloids Surf B Biointerfaces 86: 58–64. https://doi.org/10.1016/j.colsurfb.2011.03.016; PMid:21497071

10. Anukam K, Osazuwa E, Ahonkhai I, Ngwu M, Osemene G, Bruce AW. 2006. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microb Infect. 8:1450–1454. https://doi.org/10.1016/j.micinf.2006.01.003; PMid:16697231

11. Cadieux P, Burton JC, Gardiner I. 2002. Lactobacillus strains and vaginal ecology. JAMA. 287: 1940–2041. https://doi.org/10.1001/jama.287.15.1940; PMid:11960535

12. Bodean O, Munteanu O, Cirstoiu C et al. 2013. Probiotics a helpful additional therapy for bacterial vaginosis. J Med Life 4;6: 434–436.

13. Abad CL, Safdar N. 2009. The role of Lactobacillus probiotics in the treatment or prevention of urogenital infection – a systematic review. J Chemother 21 (3):243–252. https://doi.org/10.1179/joc.2009.21.3.243; PMid:19567343

14. Ehrström S, Daroczy K, Rylander E, Samuelsson C et al. 2010. Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis. Microbes Infect. 12: 691–699. https://doi.org/10.1016/j.micinf.2010.04.010; PMid:20472091